Evidence map›Paper›PMID 36915979›Full record

ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2022

Guidance on the management of adverse reactions induced by poly(ADP-ribose) polymerase inhibitors.

Society of Obstetrics and Gynecology of Zhejiang Medical Association, Society of Urology of Zhejiang Medical Association, Committee of Breast Cancer of Zhejiang Anticancer Association, Committee of Clinical Pharmacy on Oncology of Zhejiang Anticancer Association (preparation), Committee of Urology of Zhejiang Society for Mathematical Medicine

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CarboxymethylatedFood science & nutrition · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Society of Obstetrics and Gynecology of Zhejiang Medical Association
Society of Urology of Zhejiang Medical Association
Committee of Breast Cancer of Zhejiang Anticancer Association
Committee of Clinical Pharmacy on Oncology of Zhejiang Anticancer Association (preparation)
Committee of Urology of Zhejiang Society for Mathematical Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The common adverse reactions caused by poly (ADP-ribose) polymerase (PARP) inhibitors include hematological toxicity, gastrointestinal toxicity and fatigue. The main prevention and treatment of hematological toxicity include: regular blood tests, referral to hematology department when routine treatment is ineffective, and being alert of myelodysplastic syndrome/acute myeloid leukemia. The key points to deal with gastrointestinal toxicity include: taking medicine at the right time, light diet, appropriate amount of drinking water, timely symptomatic treatment, prevention of expected nausea and vomiting, and so on. For fatigue, full assessment should be completed before treatment because the causes of fatigue are various; the management includes massage therapy, psychosocial interventions and drugs such as methylphenidate and

Indexed as

PhthalazinesPoly(ADP-ribose) Polymerase InhibitorsFatigueHumansPoly(ADP-ribose) PolymerasesfluzoparibPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesAdverse reactionClinical managementExpert opinionPARPPoly (ADP-ribose) polymerase inhibitors

Identifiers

PMID36915979
PMCPMC10262009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.